carbidopa, levodopa drug combination has been researched along with Cognitive Dysfunction in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Belcaro, G; Cesarone, MR; Cotellese, R; Feragalli, B; Hosoi, M; Hu, S; Ledda, A; Maione, C; Scipione, C; Scipione, V | 1 |
| Awad, N; Roy, D; Song, J; Zamudio, P | 1 |
| Centonze, D; Fasano, A; Femiano, C; Lena, F; Modugno, N; Olivola, E; Santilli, M; Varanese, S | 1 |
3 other study(ies) available for carbidopa, levodopa drug combination and Cognitive Dysfunction
| Article | Year |
|---|---|
Supplementary management with Pycnogenol® in Parkinson's disease to prevent cognitive impairment.
Topics: Carbidopa; Cognition; Cognitive Dysfunction; Dietary Supplements; Drug Combinations; Female; Free Radicals; Humans; Levodopa; Male; Middle Aged; Oxidative Stress; Parkinson Disease; Registries | 2020 |
Treatment of unexplained coma and hypokinetic-rigid syndrome in a patient with COVID-19.
Topics: Blood Coagulation; Brain Diseases; Carbidopa; Central Nervous System Stimulants; Cognitive Dysfunction; COVID-19; Critical Care; Drug Combinations; Humans; Hypokinesia; Ischemic Stroke; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Modafinil; Rehabilitation; Respiration, Artificial; SARS-CoV-2; Severity of Illness Index; Treatment Outcome; Ventilator Weaning | 2021 |
Continuous subcutaneous apomorphine infusion in Parkinson's disease: causes of discontinuation and subsequent treatment strategies.
Topics: Adult; Aged; Aged, 80 and over; Apomorphine; Carbidopa; Cognitive Dysfunction; Deep Brain Stimulation; Dopamine Agonists; Drug Combinations; Drug Substitution; Electronic Health Records; Female; Humans; Infusions, Subcutaneous; Levodopa; Male; Medication Adherence; Middle Aged; Parkinson Disease; Retrospective Studies | 2019 |